Novo Nordisk A/S has revised its 2025 sales forecast for the fourth time in 2023, attributing the adjustment to weaker-than-anticipated demand for its leading medications, Wegovy...
Denmark’s leading corporations, Novo Nordisk A/S and Orsted A/S, are experiencing significant setbacks that raise concerns about the future of the Nordic nation’s economy. Recently, Novo...
